Literature DB >> 25618031

Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stability.

Hilla-Lee Veiner1, Rostic Gorbatov1, Moshe Vardi2, Gheorghe Doros2, Rachel Miller-Lotan1, Yaniv Zohar1, Edmond Sabo1, Rabea Asleh1, Nina S Levy1, Levi J Goldfarb1, Thomas A Berk3, Tali Haas1, Hadar Shalom1, Edith Suss-Toby1, Adi Kam1, Marielle Kaplan4, Ronit Tamir4, Anna Ziskind4, Andrew P Levy5.   

Abstract

OBJECTIVE: Homozygosity for a 1.7 kb intragenic duplication of the Haptoglobin (Hp) gene (Hp 2-2 genotype), present in 36% of the population, has been associated with a 2-3 fold increased incidence of atherothrombosis in individuals with Diabetes (DM) in 10 longitudinal studies compared to DM individuals not homozygous for this duplication (Hp 1-1/2-1). The increased CVD risk associated with the Hp 2-2 genotype has been shown to be prevented with vitamin E supplementation in man. We sought to determine if there was an interaction between the Hp genotype and vitamin E on atherosclerotic plaque growth and stability in a transgenic model of the Hp polymorphism. METHODS AND
RESULTS: Brachiocephalic artery atherosclerotic plaque volume was serially assessed by high resolution ultrasound in 28 Hp 1-1 and 26 Hp 2-2 mice in a C57Bl/6 ApoE(-/-) background. Hp 2-2 mice had more rapid plaque growth and an increased incidence of plaque hemorrhage and rupture. Vitamin E significantly reduced plaque growth in Hp 2-2 but not in Hp 1-1 mice with a significant pharmacogenomic interaction between the Hp genotype and vitamin E on plaque growth.
CONCLUSIONS: These results may help explain why vitamin E supplementation in man can prevent CVD in Hp 2-2 DM but not in non Hp 2-2 DM individuals.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Brachiocephalic artery plaque; Diabetes; Haptoglobin; Pharmacogenomics; Vitamin E

Mesh:

Substances:

Year:  2015        PMID: 25618031      PMCID: PMC4331216          DOI: 10.1016/j.atherosclerosis.2015.01.008

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  42 in total

Review 1.  Intraplaque hemorrhage.

Authors:  A P Levy; P R Moreno
Journal:  Curr Mol Med       Date:  2006-08       Impact factor: 2.222

2.  Protective effect of vitamin E supplements on experimental atherosclerosis is modest and depends on preexisting vitamin E deficiency.

Authors:  Cacang Suarna; Ben J Wu; Katherine Choy; Trevor Mori; Kevin Croft; Osamu Cynshi; Roland Stocker
Journal:  Free Radic Biol Med       Date:  2006-06-07       Impact factor: 7.376

3.  Haptoglobin genotype-dependent differences in macrophage lysosomal oxidative injury.

Authors:  Rabea Asleh; John Ward; Nina S Levy; Shady Safuri; Doron Aronson; Andrew P Levy
Journal:  J Biol Chem       Date:  2014-04-28       Impact factor: 5.157

4.  Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque.

Authors:  Andrew P Levy; Joanne E Levy; Shiri Kalet-Litman; Rachel Miller-Lotan; Nina S Levy; Roy Asaf; Julia Guetta; Chingwen Yang; K Raman Purushothaman; Valentin Fuster; Pedro R Moreno
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-10-26       Impact factor: 8.311

5.  Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo.

Authors:  Rabea Asleh; Rachael Miller-Lotan; Michael Aviram; Tony Hayek; Michael Yulish; Joanne E Levy; Benjamin Miller; Shany Blum; Uzi Milman; Chen Shapira; Andrew P Levy
Journal:  Circ Res       Date:  2006-11-02       Impact factor: 17.367

Review 6.  Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage.

Authors:  Renu Virmani; Frank D Kolodgie; Allen P Burke; Aloke V Finn; Herman K Gold; Thomas N Tulenko; Steven P Wrenn; Jagat Narula
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-07-21       Impact factor: 8.311

7.  Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin.

Authors:  Leah E Cahill; Andrew P Levy; Stephanie E Chiuve; Majken K Jensen; Hong Wang; Nawar M Shara; Shany Blum; Barbara V Howard; Jennifer K Pai; Kenneth J Mukamal; Kathryn M Rexrode; Eric B Rimm
Journal:  J Am Coll Cardiol       Date:  2013-01-09       Impact factor: 24.094

Review 8.  Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection.

Authors:  Moshe Vardi; Nina S Levy; Andrew P Levy
Journal:  J Lipid Res       Date:  2013-03-15       Impact factor: 5.922

9.  Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL.

Authors:  Vladimir V Bamm; Vladimir A Tsemakhovich; Matityahu Shaklai; Nurith Shaklai
Journal:  Biochemistry       Date:  2004-04-06       Impact factor: 3.162

10.  Genetic analysis of haptoglobin polymorphisms with cardiovascular disease and type 2 diabetes in the Diabetes Heart Study.

Authors:  Jeremy N Adams; Amanda J Cox; Barry I Freedman; Carl D Langefeld; J Jeffrey Carr; Donald W Bowden
Journal:  Cardiovasc Diabetol       Date:  2013-02-11       Impact factor: 9.951

View more
  3 in total

Review 1.  Ferroptosis: the potential value target in atherosclerosis.

Authors:  Siyu Ouyang; Jia You; Chenxi Zhi; Pin Li; Xiaoyan Lin; Xiaoqian Tan; Wentao Ma; Liang Li; Wei Xie
Journal:  Cell Death Dis       Date:  2021-08-10       Impact factor: 8.469

2.  Haptoglobin: an emerging candidate for phenotypic modulation of sickle cell anemia?

Authors:  Magnun Nueldo Nunes Dos Santos
Journal:  Rev Bras Hematol Hemoter       Date:  2015-10-09

3.  Role of Haptoglobin in Health and Disease: A Focus on Diabetes.

Authors:  Mark MacKellar; David J Vigerust
Journal:  Clin Diabetes       Date:  2016-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.